Which has preferable earnings and valuation, TLX or BBIO?

Telix Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 5.03 -$7.12M N/A N/A BridgeBio Pharma $502.08M 28.23 -$724.93M -$3.57 N/A

Is TLX or BBIO more profitable?

Telix Pharmaceuticals has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. Company Net Margins Return on Equity Return on Assets Telix Pharmaceuticals N/A N/A N/A BridgeBio Pharma -97.03% N/A -61.19%

Does the media favor TLX or BBIO?

In the previous week, BridgeBio Pharma had 19 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 24 mentions for BridgeBio Pharma and 5 mentions for Telix Pharmaceuticals. BridgeBio Pharma's average media sentiment score of 0.34 beat Telix Pharmaceuticals' score of 0.23 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Pharma 8 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, EXEL or TLX?

Exelixis has higher revenue and earnings than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.32B 6.13 $782.57M $3.18 18.06 Telix Pharmaceuticals $803.79M 5.03 -$7.12M N/A N/A

Does the media prefer EXEL or TLX?

In the previous week, Exelixis had 18 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 23 mentions for Exelixis and 5 mentions for Telix Pharmaceuticals. Exelixis' average media sentiment score of 1.07 beat Telix Pharmaceuticals' score of 0.23 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 11 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telix Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, SMMT or TLX?

Telix Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Summit Therapeutics N/A N/A -$1.08B -$1.12 N/A Telix Pharmaceuticals $803.79M 5.03 -$7.12M N/A N/A

Is SMMT or TLX more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -168.94% -141.92% Telix Pharmaceuticals N/A N/A N/A

Does the media refer more to SMMT or TLX?

In the previous week, Summit Therapeutics had 7 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 12 mentions for Summit Therapeutics and 5 mentions for Telix Pharmaceuticals. Summit Therapeutics' average media sentiment score of 0.84 beat Telix Pharmaceuticals' score of 0.23 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telix Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, BMRN or TLX?

BioMarin Pharmaceutical has higher revenue and earnings than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioMarin Pharmaceutical $3.22B 3.94 $348.90M $0.37 177.05 Telix Pharmaceuticals $803.79M 5.03 -$7.12M N/A N/A

Does the media prefer BMRN or TLX?

In the previous week, BioMarin Pharmaceutical had 12 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 17 mentions for BioMarin Pharmaceutical and 5 mentions for Telix Pharmaceuticals. BioMarin Pharmaceutical's average media sentiment score of 0.68 beat Telix Pharmaceuticals' score of 0.23 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 7 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Telix Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, MDGL or TLX?

Telix Pharmaceuticals has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Madrigal Pharmaceuticals $958.40M 12.85 -$288.28M -$12.89 N/A Telix Pharmaceuticals $803.79M 5.03 -$7.12M N/A N/A

Does the media prefer MDGL or TLX?

In the previous week, Madrigal Pharmaceuticals had 1 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 6 mentions for Madrigal Pharmaceuticals and 5 mentions for Telix Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 1.45 beat Telix Pharmaceuticals' score of 0.23 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telix Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Telix Pharmaceuticals (TLX) Competitors

$11.90 -0.44 (-3.57%)

Closing price 09/10/2026 04:00 PM Eastern

Extended Trading

$12.36 +0.46 (+3.86%)

As of 06:00 AM Eastern

Compare

TLX vs. BBIO, EXEL, SMMT, BMRN, and MDGL

Should you buy Telix Pharmaceuticals stock or one of its competitors? Telix Pharmaceuticals's main competitors and comparable companies include BridgeBio Pharma (BBIO), Exelixis (EXEL), Summit Therapeutics (SMMT), BioMarin Pharmaceutical (BMRN), and Madrigal Pharmaceuticals (MDGL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Telix Pharmaceuticals compare to BridgeBio Pharma?

Telix Pharmaceuticals (NASDAQ:TLX) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Telix Pharmaceuticals has a beta of -0.17, indicating that its stock price is 117% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

In the previous week, BridgeBio Pharma had 19 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 24 mentions for BridgeBio Pharma and 5 mentions for Telix Pharmaceuticals. BridgeBio Pharma's average media sentiment score of 0.34 beat Telix Pharmaceuticals' score of 0.23 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
BridgeBio Pharma	8 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Telix Pharmaceuticals presently has a consensus target price of $20.40, suggesting a potential upside of 71.43%. BridgeBio Pharma has a consensus target price of $101.53, suggesting a potential upside of 40.04%. Given Telix Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Telix Pharmaceuticals is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

99.9% of BridgeBio Pharma shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Telix Pharmaceuticals has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
BridgeBio Pharma	-97.03%	N/A	-61.19%

Telix Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	5.03	-$7.12M	N/A	N/A
BridgeBio Pharma	$502.08M	28.23	-$724.93M	-$3.57	N/A

Summary

Telix Pharmaceuticals and BridgeBio Pharma tied by winning 7 of the 14 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Telix Pharmaceuticals (NASDAQ:TLX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

In the previous week, Exelixis had 18 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 23 mentions for Exelixis and 5 mentions for Telix Pharmaceuticals. Exelixis' average media sentiment score of 1.07 beat Telix Pharmaceuticals' score of 0.23 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	11 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telix Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

85.3% of Exelixis shares are held by institutional investors. 2.6% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Exelixis has a net margin of 35.33% compared to Telix Pharmaceuticals' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Telix Pharmaceuticals	N/A	N/A	N/A

Exelixis has higher revenue and earnings than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.13	$782.57M	$3.18	18.06
Telix Pharmaceuticals	$803.79M	5.03	-$7.12M	N/A	N/A

Exelixis presently has a consensus price target of $50.07, suggesting a potential downside of 12.82%. Telix Pharmaceuticals has a consensus price target of $20.40, suggesting a potential upside of 71.43%. Given Telix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Telix Pharmaceuticals is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
Telix Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86

Exelixis has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.17, indicating that its share price is 117% less volatile than the broader market.

Summary

Exelixis beats Telix Pharmaceuticals on 12 of the 14 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Telix Pharmaceuticals (NASDAQ:TLX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Telix Pharmaceuticals' return on equity of 0.00% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
Telix Pharmaceuticals	N/A	N/A	N/A

Summit Therapeutics currently has a consensus target price of $25.91, suggesting a potential upside of 52.40%. Telix Pharmaceuticals has a consensus target price of $20.40, suggesting a potential upside of 71.43%. Given Telix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Telix Pharmaceuticals is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.47
Telix Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86

4.6% of Summit Therapeutics shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Summit Therapeutics had 7 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 12 mentions for Summit Therapeutics and 5 mentions for Telix Pharmaceuticals. Summit Therapeutics' average media sentiment score of 0.84 beat Telix Pharmaceuticals' score of 0.23 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	7 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telix Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summit Therapeutics has a beta of -1.24, suggesting that its stock price is 224% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.17, suggesting that its stock price is 117% less volatile than the broader market.

Telix Pharmaceuticals has higher revenue and earnings than Summit Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
Telix Pharmaceuticals	$803.79M	5.03	-$7.12M	N/A	N/A

Summary

Telix Pharmaceuticals beats Summit Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Telix Pharmaceuticals (NASDAQ:TLX) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

BioMarin Pharmaceutical has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.17, indicating that its stock price is 117% less volatile than the broader market.

BioMarin Pharmaceutical has a net margin of 2.14% compared to Telix Pharmaceuticals' net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
Telix Pharmaceuticals	N/A	N/A	N/A

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 0.7% of BioMarin Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

BioMarin Pharmaceutical currently has a consensus target price of $89.17, indicating a potential upside of 36.12%. Telix Pharmaceuticals has a consensus target price of $20.40, indicating a potential upside of 71.43%. Given Telix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Telix Pharmaceuticals is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	2.74
Telix Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, BioMarin Pharmaceutical had 12 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 17 mentions for BioMarin Pharmaceutical and 5 mentions for Telix Pharmaceuticals. BioMarin Pharmaceutical's average media sentiment score of 0.68 beat Telix Pharmaceuticals' score of 0.23 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	7 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Telix Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioMarin Pharmaceutical has higher revenue and earnings than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	3.94	$348.90M	$0.37	177.05
Telix Pharmaceuticals	$803.79M	5.03	-$7.12M	N/A	N/A

Summary

BioMarin Pharmaceutical beats Telix Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Telix Pharmaceuticals (NASDAQ:TLX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations and risk.

In the previous week, Madrigal Pharmaceuticals had 1 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 6 mentions for Madrigal Pharmaceuticals and 5 mentions for Telix Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 1.45 beat Telix Pharmaceuticals' score of 0.23 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telix Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Telix Pharmaceuticals has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Telix Pharmaceuticals' return on equity of 0.00% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%
Telix Pharmaceuticals	N/A	N/A	N/A

Madrigal Pharmaceuticals presently has a consensus price target of $699.64, indicating a potential upside of 31.24%. Telix Pharmaceuticals has a consensus price target of $20.40, indicating a potential upside of 71.43%. Given Telix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Telix Pharmaceuticals is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
Telix Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86

Telix Pharmaceuticals has lower revenue, but higher earnings than Madrigal Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40M	12.85	-$288.28M	-$12.89	N/A
Telix Pharmaceuticals	$803.79M	5.03	-$7.12M	N/A	N/A

Madrigal Pharmaceuticals has a beta of -0.98, suggesting that its share price is 198% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.17, suggesting that its share price is 117% less volatile than the broader market.

Summary

Telix Pharmaceuticals beats Madrigal Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Telix Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TLX vs. The Competition

Export

Metric	Telix Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.19B	$3.88B	$7.21B	$12.81B
Dividend Yield	N/A	3.63%	2.56%	10.55%
P/E Ratio	N/A	13.60	272.83	25.11
Price / Sales	5.03	1,340.82	623.31	90.53
Price / Cash	292.67	106.61	77.33	51.83
Price / Book	9.67	15.30	10.38	6.18
Net Income	-$7.12M	-$22.82M	$3.49B	$358.18M
7 Day Performance	-0.34%	-3.93%	-3.16%	-2.51%
1 Month Performance	-0.83%	0.29%	0.02%	-2.73%
1 Year Performance	27.68%	38.63%	17.32%	7.73%

Telix Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TLX Telix Pharmaceuticals	3.1984 of 5 stars	$11.90 -3.6%	$20.40 +71.4%	+22.8%	$4.19B	$803.79M	N/A	1,184
BBIO BridgeBio Pharma	3.437 of 5 stars	$75.18 +0.5%	$101.53 +35.0%	+36.9%	$14.72B	$502.08M	N/A	400	Trending News Analyst Forecast
EXEL Exelixis	2.5378 of 5 stars	$58.38 -1.1%	$50.07 -14.2%	+52.3%	$14.50B	$2.32B	18.40	1,077	Positive News
SMMT Summit Therapeutics	3.4115 of 5 stars	$17.32 -1.6%	$24.07 +39.0%	-3.4%	$13.83B	N/A	N/A	110	Analyst Forecast
BMRN BioMarin Pharmaceutical	4.6951 of 5 stars	$65.38 -1.7%	$89.17 +36.4%	+20.2%	$12.66B	$3.22B	176.82	3,221	Trending News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TLX) was last updated on 9/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Telix Pharmaceuticals (TLX) Competitors

TLX vs. BBIO, EXEL, SMMT, BMRN, and MDGL

How does Telix Pharmaceuticals compare to BridgeBio Pharma?

Summary

How does Telix Pharmaceuticals compare to Exelixis?

Summary

How does Telix Pharmaceuticals compare to Summit Therapeutics?

Summary

How does Telix Pharmaceuticals compare to BioMarin Pharmaceutical?

Summary

How does Telix Pharmaceuticals compare to Madrigal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLX vs. The Competition

Telix Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Telix Pharmaceuticals (TLX) Competitors

TLX vs. BBIO, EXEL, SMMT, BMRN, and MDGL

How does Telix Pharmaceuticals compare to BridgeBio Pharma?

Which has more volatility & risk, TLX or BBIO?

Does the media favor TLX or BBIO?

Do analysts rate TLX or BBIO?

Do institutionals and insiders hold more shares of TLX or BBIO?

Is TLX or BBIO more profitable?

Which has preferable earnings and valuation, TLX or BBIO?

Summary

How does Telix Pharmaceuticals compare to Exelixis?

Does the media prefer EXEL or TLX?

Do insiders and institutionals believe in EXEL or TLX?

Is EXEL or TLX more profitable?

Which has preferable earnings & valuation, EXEL or TLX?

Do analysts prefer EXEL or TLX?

Which has more risk and volatility, EXEL or TLX?

Summary

How does Telix Pharmaceuticals compare to Summit Therapeutics?

Is SMMT or TLX more profitable?

Do analysts recommend SMMT or TLX?

Do institutionals & insiders hold more shares of SMMT or TLX?

Does the media refer more to SMMT or TLX?

Which has more risk and volatility, SMMT or TLX?

Which has stronger valuation and earnings, SMMT or TLX?

Summary

How does Telix Pharmaceuticals compare to BioMarin Pharmaceutical?

Which has more risk and volatility, BMRN or TLX?

Is BMRN or TLX more profitable?

Do institutionals & insiders have more ownership in BMRN or TLX?

Do analysts rate BMRN or TLX?

Does the media prefer BMRN or TLX?

Which has preferable valuation and earnings, BMRN or TLX?

Summary

How does Telix Pharmaceuticals compare to Madrigal Pharmaceuticals?

Does the media prefer MDGL or TLX?

Do institutionals and insiders believe in MDGL or TLX?

Is MDGL or TLX more profitable?

Do analysts prefer MDGL or TLX?

Which has preferable earnings and valuation, MDGL or TLX?

Which has more risk and volatility, MDGL or TLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLX vs. The Competition

Telix Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools